Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11145088 | 0.94 | — | — | |
| SCHEMBL4890557 | 0.82 | HTR6 (0.34) | HTR6 | |
| SCHEMBL1138718 | 0.72 | HTR6 (0.46) | HTR6 | |
| SCHEMBL28045452 | 0.70 | — | — | |
| SCHEMBL11188231 | 0.68 | HTR6 (0.46) | HTR6 | |
| SCHEMBL6743417 | 0.67 | HTR6 (0.44) | HTR6 | |
| SCHEMBL6406378 | 0.65 | — | — | |
| SCHEMBL6498117 | 0.65 | — | — | |
| SCHEMBL2331298 | 0.65 | — | — | |
| SCHEMBL7462352 | 0.64 | HTR6 (0.33) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1536782-B1 | SYNERGISTIC COMBINATION OF AN ALPHA-2-DELTA LIGAND AND A PDEV INHIBITOR FOR USE IN THE TREATMENT OF PAIN | PFIZER LTD (GB) | 2007-04-18 | — | — | EP | disclosed |
| EP-1536782-A1 | SYNERGISTIC COMBINATION OF AN ALPHA-2-DELTA LIGAND AND A PDEV INHIBITOR FOR USE IN THE TREATMENT OF PAIN | Pfizer Limited (GB) | 2005-06-08 | — | — | EP | disclosed |
| US-20040092522-A1 | Synergistic combinations | FIELD MARK JOHN (GB) | 2004-05-13 | — | — | US | disclosed |
| WO-2004016259-A1 | SYNERGISTIC COMBINATION OF AN ALPHA-2-DELTA LIGAND AND A PDEV INHIBITOR FOR USE IN THE TREATMENT OF PAIN | PFIZER LIMITED (GB) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092522-A1 | Synergistic combinations | PDE2A, PDE1B, PDE1A | HTR6 1893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.